Literature DB >> 9579835

Adjuvant therapy for melanoma: How should we respond to high-dose interferon?

P G de Takats1, M V Williams, R Hawkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9579835      PMCID： PMC2150169          DOI： 10.1038/bjc.1998.215

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  37 in total

1.  A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.

Authors:  L E Spitler
Journal:  J Clin Oncol       Date:  1991-05       Impact factor: 44.544

2.  Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma.

Authors:  F L Meyskens; K Kopecky; M Samson; E Hersh; J Macdonald; H Jaffe; J Crowley; C Coltman
Journal:  J Natl Cancer Inst       Date:  1990-06-20       Impact factor: 13.506

3.  Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.

Authors:  C I Falkson; G Falkson; H C Falkson
Journal:  J Clin Oncol       Date:  1991-08       Impact factor: 44.544

4.  Results of adjuvant interferon study in WHO melanoma programme.

Authors:  N Cascinelli; R Bufalino; A Morabito; R Mackie
Journal:  Lancet       Date:  1994-04-09       Impact factor: 79.321

5.  Technical details of intraoperative lymphatic mapping for early stage melanoma.

Authors:  D L Morton; D R Wen; J H Wong; J S Economou; L A Cagle; F K Storm; L J Foshag; A J Cochran
Journal:  Arch Surg       Date:  1992-04

6.  Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction.

Authors:  B Smith; P Selby; J Southgate; K Pittman; C Bradley; G E Blair
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

7.  Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.

Authors:  E Bajetta; A Di Leo; M G Zampino; M R Sertoli; G Comella; M Barduagni; B Giannotti; P Queirolo; G Tribbia; M G Bernengo
Journal:  J Clin Oncol       Date:  1994-04       Impact factor: 44.544

Review 8.  Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer.

Authors:  H C Stevenson; I Green; J M Hamilton; B A Calabro; D R Parkinson
Journal:  J Clin Oncol       Date:  1991-11       Impact factor: 44.544

9.  Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.

Authors:  B R Meisenberg; M Ross; J J Vredenburgh; R Jones; E J Shpall; H F Seigler; D M Coniglio; K Wu; W P Peters
Journal:  J Natl Cancer Inst       Date:  1993-07-07       Impact factor: 13.506

10.  Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.

Authors:  D B Thomson; M Adena; G R McLeod; P Hersey; P G Gill; A S Coates; I N Olver; R F Kefford; R M Lowenthal; G F Beadle
Journal:  Melanoma Res       Date:  1993-04       Impact factor: 3.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.